

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number:

48-00988-04

Docket or Reference number:

030-03415

Amendment No. 40

CORRECTED COPY

Good Samaritan Hospital
2000 W. Kilbourn Ave.
Milwaukee, WI 53233

In accordance with letters dated May 11, 1987 and June 25, 1987, License Number 48-00988-04 is amended as follows:

Items 6., 7., 8., and 9. are amended to add:

6. Byproduct, source,
and/or special nuclear
material

7. Chemical and/or
physical form

8. Maximum amount that
licensee may possess
at any one time
under this license

F. Gadolinium-153

F. Sealed Sources
(Norland Model No.
N1077)

F. 2 sources not
to exceed 1.5
curies each

9. Authorized Use

F. For use in Norland Model 2600 Bone Densitometer for human bone mineral analysis.

Conditions 12. and 18. are amended as follows:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

J. R. Kasner, M.D.

Groups I, II and III
Iodine-131 for therapy
Soluble phosphorus-32 for therapy
Xenon-133
Gadolinium-153 for bone mineral
analysis

Bert D. Collier, Jr., M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies
Gadolinium-153 for bone mineral
analysis

Howard H. Johnson, M.D.

Groups I, II and III
Xenon-133
Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction, and thyroid carcinoma
Gadolinium-153

8801220004 870810
REG3 LIC30
48-00988-04 PDR

11 2463 P.V.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

48-00988-04

Docket or Reference number

030-03415

Amendment No. 40

CORRECTED COPY

George C. Bares, M.D.

Groups I, II and III

Xenon-133

Gadolinium-153 for bone mineral analysis

Roland C. Brown, M.D.

Groups I, II and III

Xenon-133

Gadolinium-153 for bone mineral analysis

William J. Pier, Jr., M.D.

Groups I, II and III

Xenon-133

Gadolinium-153 for bone mineral analysis

Marcia G. S. Richards, M.D.

Group VI

Depleted Uranium

P. Veluvolu, M.D.

Groups I, II and III

Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction and thyroid carcinoma
Soluble phosphorus-32 for treatment
of polycythemia vera, leukemia
and bone metastases

Xenon-133

In vitro studies

Gadolinium-153 for bone mineral analysis

John P. Whalen, M.D.

Groups I, II and III

Iodine-131 for treatment of
hyperthyroidis, cardiac
dysfunction and thyroid carcinoma
Soluble phosphorus-32 for treatment
of polycythemia vera, leukemia
and bone metastases

Xenon-133

In vitro studies

Gadolinium-153 for bone mineral analysis

James E. Bruckman, M.D.

Group VI

Gadolinium-153 for bone mineral analysis

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

48-00988-04

Docket or Reference number

030-03415

Amendment No. 40

CORRECTED COPY

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 25, 1985; and

B. Letters dated January 7, 1985, January 15, 1985, April 3, 1985, June 18, 1985, July 12, 1985, August 1, 1985, May 11, 1987 and June 25, 1987.

For the U.S. Nuclear Regulatory Commission

Date August 10, 1987

Original Signed
By Patricia M. Vacherlon
Materials Licensing Section, Region III